Atomo Diagnostics (ASX:AT1) Dividends Paid: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Atomo Diagnostics Dividends Paid?

Atomo Diagnostics ASX:AT1 Dividends Paid is A$0.00 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Atomo Diagnostics's Dividends Paid for the six months ended in Dec. 2025 was A$0.00 Mil.

Atomo Diagnostics's Dividends Paid for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Atomo Diagnostics Dividends Paid Related Terms

Atomo Diagnostics Dividends Paid Historical Data

* Premium members only.

The historical data trend for Atomo Diagnostics's Dividends Paid can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics Dividends Paid Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Dividends Paid
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividends Paid Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Atomo Diagnostics Dividends Paid Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Dividends Paid represents dividend paid to the investors in the direct cash flow method.

Dividends Paid for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividends Paid →
What does a Dividends Paid of A$0.00 Mil mean?
Atomo Diagnostics (ASX:AT1) has a Dividends Paid of A$0.00 Mil as of Dec. 2025. Dividends Paid represents dividend paid to the investors in direct cash flow method. View historical data for Atomo Diagnostics and its competitors.
Is Atomo Diagnostics' Dividends Paid too high?
Atomo Diagnostics' current Dividends Paid is A$0.00 Mil.
How does Atomo Diagnostics' Dividends Paid compare to ABT and SYK?
Atomo Diagnostics' Dividends Paid of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends Paid for a Medical Devices & Instruments company?
A good Dividends Paid depends on the Medical Devices & Instruments industry context. However, Dividends Paid should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends Paid mean?
A high Dividends Paid can signal that a stock is expensive relative to its fundamentals. Dividends Paid represents dividend paid to the investors in direct cash flow method. View historical data for Atomo Diagnostics and its competitors. Atomo Diagnostics's current Dividends Paid is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 10% below its estimated fair value. The current Dividends Paid is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends Paid calculated?
Dividends Paid is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Dividends Paid is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atomo Diagnostics Business Description

Address 3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.